Is Compounded GLP-1 Legit and Safe?

"Compounded" is the word that makes new GLP-1 patients nervous, and it should prompt questions — but not panic. Compounding is a legal, long-established part of American pharmacy. What it is not is FDA-approved in the way Wegovy or Zepbound are. Understanding that distinction is the difference between a reasonable, cost-driven choice and a genuinely risky one.

What "legit" actually means here

Pharmacy compounding — preparing a medication tailored to a prescription rather than buying a manufacturer's finished product — is lawful and regulated. The key fact to hold onto is that compounded drugs are not FDA-approved: the FDA does not verify their safety, effectiveness, or quality before they reach patients¹. So the honest answer to "is it legit?" is: compounding itself is legitimate, but the individual product has not passed the FDA review that branded drugs have. That raises the stakes on choosing the pharmacy well.

503A vs 503B: the distinction that matters

Federal law splits compounding into two lanes, and the difference is worth knowing²:

• 503A pharmacies compound against individual patient prescriptions. They are overseen primarily by state boards of pharmacy and are not required to follow the FDA's full manufacturing standards.
• 503B outsourcing facilities voluntarily register with the FDA, can compound larger batches, and must follow Current Good Manufacturing Practice (CGMP) — the same quality framework that governs conventional drug manufacturers, with FDA inspection.

Neither produces an FDA-approved drug. For GLP-1s specifically, though, the more important question in 2026 is not which lane is stricter but which lane is still open.

What changed in 2025 and 2026

Both lanes could compound semaglutide and tirzepatide freely only while those drugs sat on the FDA's drug shortage list. The FDA declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025³. It then set grace periods, and they have all run out: for 503A pharmacies, enforcement discretion for tirzepatide ended after a federal court's March 5, 2025 ruling and for semaglutide after its April 24, 2025 ruling; for 503B outsourcing facilities, it ran until March 19, 2025 (tirzepatide) and May 22, 2025 (semaglutide)³.

As of April 1, 2026, the FDA's position is that "tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list" — and an outsourcing facility may compound from bulk ingredient only when one of those two conditions holds³. On April 30, 2026, the agency went a step further and proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, "finding no clinical need for outsourcing facilities to compound these drugs from bulk substances"⁴. The Federal Register notice of May 1, 2026 opened a comment period⁵ that the FDA later extended to July 30, 2026⁶. As of August 2026, we could not find a published final determination; until one appears, the proposal is a proposal, not a rule.

What remains is the 503A lane, and it has conditions. In its April 1, 2026 reminder, the FDA said a 503A product must be compounded for an individual patient on a prescription, and that the pharmacy must not compound "regularly or in inordinate amounts" drugs that are essentially copies of a commercially available product — unless a prescriber documents a change that makes a significant difference for that patient³. That is why the compounded GLP-1 market today runs almost entirely through state-licensed 503A pharmacies, and why a provider's prescribing and formulation paperwork matters more than it did a year ago.

Why LegitScript verification matters

Because you cannot inspect a pharmacy yourself, third-party certification is a practical proxy for trust. LegitScript is an independent service that certifies healthcare merchants and pharmacies against legal and safety standards, and it is the certification the major ad platforms require of telehealth advertisers. A LegitScript-verified operator has cleared an outside review of its licensing and practices. It is not the same as FDA approval of the drug, but it is a meaningful signal that the seller is who it says it is. In our ranking, providers such as Ondra Health are noted as LegitScript-verified.

How to vet a compounded GLP-1 provider

Before you buy, run this short due-diligence pass:

1. Name the pharmacy. A legitimate provider will tell you which pharmacy dispenses your medication. Anonymity is the single biggest red flag.
2. Check the tier — and the date. As of August 2026, an outsourcing facility cannot lawfully compound semaglutide or tirzepatide from bulk ingredient while both drugs are off the shortage list and off the 503B bulks list³. Expect a clearly identified, state-licensed 503A pharmacy. If a provider claims a 503B source for its GLP-1 vials, ask how that squares with the FDA's current position.
3. Look for third-party certification such as LegitScript verification.
4. Confirm real clinical oversight — a licensed prescriber, intake screening, and reachable support.
5. Be wary of price-only marketing. A rock-bottom number with no pharmacy named and no clinician in sight is the pattern to avoid.
6. Be extra cautious of below-label "microdosing." Compounding is what makes below-label doses possible in the first place, and no randomized trial has tested that practice — see GLP-1 microdosing for what the evidence gap actually means.
7. Keep a record of exactly what pharmacy and formulation you use. That documentation matters beyond the initial purchase — if you ever face surgery, your anesthesia team needs to know you're on a GLP-1 drug regardless of whether it's compounded or brand-name; see GLP-1 drugs before surgery for why that disclosure changes their risk assessment.

For the full step-by-step version of this vetting pass — including how to verify a prescriber's state license and a pharmacy's accreditation yourself — see how to tell if a GLP-1 provider is legitimate.

We build exactly these factors into our scoring — "licensing and trust" is one of the six graded dimensions on every review (see our methodology).

The bottom line

Compounded GLP-1 can be a legitimate, sensible choice — millions of patients use it, and it is why access exists at prices many can sustain. The risk is not "compounded" as a category; it is choosing an anonymous, uncertified seller on price alone — which is why our ranking of compounded semaglutide providers prints a provenance column instead of assuming every unlabeled row is what it looks like. The catalog around the GLP-1 line is a signal in itself: Rehydra+, which sells oral BPC-157 beside its GLP-1 products, is offering an absorption route that has not been demonstrated for that peptide, and a seller's willingness to list one tells you how it evaluates the rest of its own shelf. Vet the pharmacy, favor certified operators, and if you would rather have the FDA-reviewed product, read compounded vs brand-name GLP-1 and filter the comparison pages to brand-capable providers. To see how the top-scored provider stacks up against the field, use the alternatives view — and for the regulatory and trial sources behind all of this, our research library.